FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
11/27/2023
Back to search
Official data from USPTO
FEXUCLUE
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
26
Latest update
11/27/2023
Trademark type
Combined
Nice classes
5
Filing date
01/19/2022
Registration date
08/01/2023
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
08/01/2023
Last transaction
08/01/2023
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
3
Owner type
03
Owner location
KR
Examiner
OSGOOD, KRYSTINA E
Law office
N30
Current location
PUBLICATION AND ISSUE SECTION
Mark description
The mark consists of the stylized wording "FEXUCLUE" in blue, wherein the inside of the letter "C" is a design of the stomach in the colors red, orange, yellow and green. The color white in the mark is background only and is not claimed as a feature of the mark.
Holders and representatives
Holders
DAEWOONG PHARMACEUTICAL CO., LTD.
Representatives
Diane J. Mason Faegre Drinker Biddle & Reath LLP
Technical classification
Nice Classes
Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical agents affecting digestive organs; medicines for treating intestinal disorders; Pharmaceutical preparations in the nature of proton-pump inhibitors for the treatment of gastroesophageal reflux diseasepeptic ulcerintestinal disordersgastrointestinal disorderserosive esophagitisgastritisgastric ulcerduodenal ulcernon-erosive reflux diseaseduodenal ulcer recurrence and pathological hypersecretory conditions including Zollinger-Ellison syndrome and combination antibiotic therapy for the treatment of Helicobacter pylori infection; medicines for the treatment of gastrointestinal diseases; medicines for human purposes for the treatment of gastroesophageal reflux diseasepeptic ulcerintestinal disordersgastrointestinal disorderserosive esophagitisgastritisgastric ulcerduodenal ulcernon-erosive reflux diseaseduodenal ulcer recurrence and pathological hypersecretory conditions including Zollinger-Ellison syndrome and combination antibiotic therapy for the treatment of Helicobacter pylori infection; pharmaceutical preparations for the treatment of gastroesophageal reflux diseasepeptic ulcerintestinal disordersgastrointestinal disorderserosive esophagitisgastritisgastric ulcerduodenal ulcernon-erosive reflux diseaseduodenal ulcer recurrence and pathological hypersecretory conditions including Zollinger-Ellison syndrome and combination antibiotic therapy for the treatment of Helicobacter pylori infection; ethical medicinal preparations for the treatment of gastroesophageal reflux diseasepeptic ulcerintestinal disordersgastrointestinal disorderserosive esophagitisgastritisgastric ulcerduodenal ulcernon-erosive reflux diseaseduodenal ulcer recurrence and pathological hypersecretory conditions including Zollinger-Ellison syndrome and combination antibiotic therapy for the treatment of Helicobacter pylori infection
Publications
History of USPTO decisions and trademark events.
26 publications found
NREP
NEW REPRESENTATIVE AT IB RECEIVED
11/10/2023
FICS
FINAL DISPOSITION NOTICE SENT TO IB
11/02/2023
FIMP
FINAL DISPOSITION PROCESSED
11/01/2023
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
11/01/2023
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
08/01/2023
R.PR
REGISTERED-PRINCIPAL REGISTER
08/01/2023
GPNX
NOTIFICATION PROCESSED BY IB
05/17/2023
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
05/16/2023
PUBO
PUBLISHED FOR OPPOSITION
05/16/2023
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
04/26/2023
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
04/26/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
04/26/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
04/13/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
03/20/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
03/17/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
03/17/2023
RFNT
REFUSAL PROCESSED BY IB
02/01/2023
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
01/12/2023
RFRR
REFUSAL PROCESSED BY MPU
01/12/2023
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
11/02/2022
CNRT
NON-FINAL ACTION WRITTEN
11/01/2022
DOCK
ASSIGNED TO EXAMINER
10/28/2022
MAFR
APPLICATION FILING RECEIPT MAILED
03/22/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
03/18/2022
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
03/17/2022
Continuous trademark protection
Get notified about every new filing that threatens FEXUCLUE or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.